Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

(2013) Lixian Zhong et al.   PLoS One

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer

(2013) Cora N Sternberg et al.   BMC Urology

Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer

(2012) T. B. Dorff et al.   ANNALS OF ONCOLOGY

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

(2011) H. Quan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden

(2011) Anders Berglund et al.   JOURNAL OF UROLOGY

A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids

(2010) David M. Poetker et al.   OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA

Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population

(2010) B. Alemayehu et al.   JOURNAL OF MEDICAL ECONOMICS

Medication Adherence

(2009) P. Michael Ho et al.   CIRCULATION

The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients

(2008) Mary E. Charlson et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY